澳华内镜(688212) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥113,420,020.99, representing a year-on-year increase of 37.96%[8] - The net profit attributable to shareholders for Q3 2022 was ¥3,514,697.77, a decrease of 69.66% compared to the same period last year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥2,808,628.35, down 75.32% year-on-year[8] - Total revenue for the first three quarters of 2022 reached ¥280,772,884.24, an increase of 22.6% compared to ¥229,113,972.10 in the same period of 2021[32] - Net profit for the first three quarters of 2022 was ¥10,263,456.13, a decrease of 54.5% from ¥22,539,049.94 in the same period of 2021[35] - The total comprehensive income for the first three quarters of 2022 was ¥8,741,000.41, down from ¥21,120,198.68 in the same period of 2021[37] - The total profit for the first three quarters of 2022 was a loss of ¥11,911,163.87, contrasting with a profit of ¥10,118,048.69 in the same period of 2021[51] Research and Development - The total R&D investment for Q3 2022 was ¥22,579,770.30, an increase of 90.23% compared to the same period last year[12] - R&D investment accounted for 19.91% of operating revenue in Q3 2022, an increase of 5.47 percentage points year-on-year[12] - Research and development expenses increased to ¥59,496,193.03 in 2022, up 68.7% from ¥35,236,256.75 in 2021[35] - Research and development expenses increased significantly to ¥59,721,194.66, up 71.2% from ¥34,885,391.56 in the previous year[50] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥63,895,060.94, a decrease of 310.42% compared to the same period last year[12] - Cash flow from operating activities for the first three quarters of 2022 was ¥260,492,218.38, compared to ¥243,100,349.50 in 2021, indicating a 7.1% increase[37] - The net cash flow from investment activities was CNY -205,746,180.24 for the first three quarters of 2022, compared to CNY -64,968,651.18 in the same period of 2021, indicating a worsening investment cash flow situation[40] - The company's cash and cash equivalents decreased to ¥466,394,364.86 from ¥766,817,412.06, representing a decline of about 39.2% year-over-year[27] - The company's total current assets decreased slightly to ¥980,439,819.97 from ¥996,905,219.79, a decline of approximately 1.6%[27] - The company's cash inflow from investment activities was CNY 590,373,712.87 in 2022, a substantial increase from CNY 105,163,388.58 in 2021, representing an increase of approximately 461.0%[40] - The company reported a net increase in cash and cash equivalents of CNY -300,423,047.20 for the first three quarters of 2022, compared to CNY -41,866,961.28 in the same period of 2021, indicating a worsening cash position[42] Assets and Liabilities - Total assets at the end of Q3 2022 were ¥1,381,637,306.61, an increase of 2.40% from the end of the previous year[12] - The company's total liabilities as of September 30, 2022, were ¥82,932,006.01, compared to ¥58,982,132.82 at the end of 2021, reflecting an increase of approximately 40.5%[30] - Non-current assets totaled ¥401,197,486.64, up from ¥352,330,037.69, which is an increase of about 13.9% year-over-year[30] - The total liabilities as of September 30, 2022, amounted to ¥126,560,495.05, compared to ¥90,356,468.99 at the end of 2021, reflecting a 40.0% increase[32] - The company's total equity decreased to CNY 1,202,889,957.60 as of September 30, 2022, down from CNY 1,218,639,646.70 at the end of December 2021, indicating a decline of about 1.3%[48] Earnings Per Share - Basic earnings per share for Q3 2022 were ¥0.02, down 81.67% year-on-year[12] - The company reported a basic earnings per share of ¥0.06 for the first three quarters of 2022, down from ¥0.21 in the same period of 2021[37] Future Outlook - The company plans to continue enhancing product upgrades and market promotion to drive future growth[16] - The company has not disclosed any new product developments or market expansion strategies in the current report[30]